Rhumbline Advisers Iveric Bio, Inc. Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$26.24 - $39.63 $229,180 - $346,128	8,734 Added 4.65%	196,612 $7.73 Million
Q1 2023 May 11, 2023	BUY	$18.67 - $24.56 $113,569 - $149,398	6,083 Added 3.35%	187,878 $4.57 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $445,619 - $619,059	25,848 Added 16.57%	181,795 $3.89 Million
Q3 2022 Nov 10, 2022	BUY	$9.4 - $18.59 $132,728 - $262,490	14,120 Added 9.96%	155,947 $2.8 Million
Q2 2022 Aug 11, 2022	SELL	$9.12 - $18.9 $35,686 - $73,955	-3,913 Reduced 2.68%	141,827 $1.36 Million
Q1 2022 May 12, 2022	BUY	$12.15 - $16.83 $31,189 - $43,202	2,567 Added 1.79%	145,740 $2.45 Million
Q4 2021 Feb 10, 2022	BUY	$13.83 - $18.78 $219,233 - $297,700	15,852 Added 12.45%	143,173 $2.39 Million
Q3 2021 Nov 12, 2021	BUY	$7.07 - $17.5 $111,451 - $275,870	15,764 Added 14.13%	127,321 $2.07 Million
Q2 2021 Aug 05, 2021	SELL	$5.69 - $7.17 $26,697 - $33,641	-4,692 Reduced 4.04%	111,557 $704,000
Q1 2021 May 06, 2021	SELL	$5.08 - $6.89 $36,830 - $49,952	-7,250 Reduced 5.87%	116,249 $718,000
Q4 2020 Feb 10, 2021	BUY	$5.65 - $7.66 $186,269 - $252,534	32,968 Added 36.42%	123,499 $853,000
Q3 2020 Nov 12, 2020	BUY	$4.01 - $6.29 $109,681 - $172,044	27,352 Added 43.29%	90,531 $511,000
Q2 2020 Aug 13, 2020	BUY	$3.06 - $6.6 $193,327 - $416,981	63,179 New	63,179 $322,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.